Current best evidence on prescribed drugs

Drugdocs Logo

Current best evidence on prescribed drugs

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Vyvgart

Chemical Nameefgartigimod alfa-fcab
Dosage FormInjection (intravenous; (20 mg/mL)
Drug ClassReceptor antagonists
SystemMusculoskeletal
CompanyArgenx
Approval Year2021

Indication

  • For the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Last updated on 2/22/2022

More on this drug: Clinical Trials

Document TitleYearSource
Vyvgart (efgartigimod alfa-fcab) Prescribing Information.2021argenx BV, Zwijnaarde, Belgium
Document TitleYearSource
Eculizumab and efgartigimod for the treatment of myasthenia gravis: effectiveness and value.2021ICER